Skip to main content
. Author manuscript; available in PMC: 2022 Mar 7.
Published in final edited form as: Clin Cancer Res. 2021 Jun 1;27(14):4025–4035. doi: 10.1158/1078-0432.CCR-21-0575

Figure 2. Impact of CDKN2A GAs on overall survival (OS) and time to treatment failure (TTF) in ICI-treated patients with melanoma and urothelial carcinoma.

Figure 2.

A. Overall survival in DFCI UC cohort. B. Time-to-failure in DFCI UC cohort. C. Overall survival in DFCI melanoma cohort. D. Time-to-failure in DFCI melanoma cohort. E. Overall survival in MSKCC UC cohort. All reported p-values are of the Wald x2 test from the Cox regression analysis, adjusted as detailed in the methods section. WT: wild type